Table 3.
Harvey–Bradshaw Index, clinical remission, and response at baseline, weeks 16, 52, and 104
| Baseline* N = 114 (%) |
Week 16** N = 105 (%) |
Week 52** N = 80 (%) |
Week 104** N = 69 (%) |
||
|---|---|---|---|---|---|
| Mild–severe clinical activity (HBI ≥ 5) | n/N (%) | 69/96 (72) | 45/70 (71) | 25/56 (45) | 15/43 (35) |
| Clinical remission (HBI ≤ 4) | n/N (%) | 27/96 (28) | 25/70 (36) | 31/56 (55) | 28/43 (65) |
| Maintained clinical remission# | n/N (%) | – | – | 13/56 (23) | 11/43 (26) |
| Clinical response¶ | n/N (%) | – | 23/50 (29) | 25/37 (68) | 20/29 (69) |
| Clinical response or remission§ | n/N (%) | – | 38/70 (54) | 42/56 (75) | 31/43 (72) |
*Includes patients with recorded HBI scores or inflammatory markers recorded within ± 2 weeks of baseline; **includes patients with recorded HBI scores or inflammatory markers within ± 2 weeks at baseline, weeks 16, 52, and 104; # remission at week 16 and still in remission at weeks 52 or 104; ¶ HBI ≥ 5 at baseline and response at weeks 16, 52, or 104; § HBI ≥ 5 at baseline and response or remission at weeks 16, 52, or 104
HBI = Harvey–Bradshaw Index